EpSSG Publications

Outcome and prognostic factors in pediatric malignant peripheral nerve sheath tumors: An analysis of the European Pediatric Soft Tissue Sarcoma Group (EpSSG) NRSTSā€2005 prospective study

Van Noesel MM, Orbach D, Brennan B, Kelsey A, Zanetti I, De Salvo GL, Gaze MN, Craigie RJ, McHugh K, Francotte N, Collini P, Bisogno G, Casanova M, Ferrari A. Pediatr Blood Cancer. 2019 Jun 26:e27833. doi: 10.1002/pbc.27833. [Epub ahead of print]

Clinical features and outcomes of young patients with epithelioid sarcoma: an analysis from the Children’s Oncology Group (COG) and the European paediatric soft tissue Sarcoma Study Group (EpSSG) prospective clinical trials

Spunt S, Francotte N, De Salvo GL, Chi YY, Zanetti I, Hayes-Jordan A, Kao S, Orbach D, Brennan B, Weiss A, Van Noesel M, Million L, Alaggio R, Parham D, Kelsey A, Randall RL, McCarville MB, Bisogno G, Hawkins D, Ferrari A, EIC Eur J Cancer. 2019 Apr 4;112:98-106. DOI: 10.1016/j.ejca.2019.02.001.

Outcome of localized liver-bile duct rhabdomyosarcoma according to local therapy. A report from the European paediatric Soft Tissue Sarcoma Study Group (EpSSG)- RMS 2005 study.

Guerin F, Rogers T, Minard-Colin V, Gaze M, Terwisscha S, van Noesel M, De Corti F, Guillen Burrieza G, De Salvo GL, Kelsey A, Orbach D, Ferrari A, Bergeron C, Bisogno G, Martelli H, Pediatr Blood Cancer. 2019 Mar 28:e27725. DOI: 10.1002/pbc.27725

Indeterminate pulmonary nodules at diagnosis in pediatric rhabdomyosarcoma: are we undertreating patients? A report from the European paediatric Soft tissue sarcoma Study Group-RMS-2005 protocol.

Vaarwerk B, Bisogno G, McHugh K, Brisse H, Morosi C, Corradini N, Jenney M, Orbach D, Chisholm J, Ferrari A, Zanetti I, De Salvo GL, Van Rijn RR, Merks JHM, EpSSG Radiology Group. J Clin Oncol. 2019 Jan 31:JCO1801535. DOI: 10.1200/JCO.18.01535

Localized vaginal/uterine rhabdomyosarcoma-results of a pooled analysis from four international cooperative groups.

Minard-Colin V, Walterhouse D, Bisogno G, Martelli H, Anderson J, Rodeberg DA, Ferrari A, Jenney M, Wolden S, De Salvo G, Arndt C, Merks JHM, Gallego S, Schwob D, Haie-Meder C, Bergeron C, Stevens MCG, Oberlin O, Hawkins D; International Society of Pediatric Oncology Sarcoma Committee, the Children's Oncology Group, the Italian Cooperative Soft Tissue Sarcoma Group, and the European pediatric Soft tissue sarcoma Study Group. Pediatr Blood Cancer. 2018 Sep;65(9):e27096. DOI: 10.1002/pbc.27096.

Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma: Results from a Pooled-Analysis of North American and European Cooperative Groups

Walterhouse D, Barkauskas D, Hall D, Ferrari A, De Salvo GL, Koscielniak E, Stevens M, Martelli H, Seitz G, Rodeberg D, Shnorhavorian M, Dasgupta R, Breneman JC, Anderson JR, Bergeron C, Bisogno G, Meyer WH, Hawkins D, Minard-Colin V. J Clin Oncol. 2018 Oct 23:JCO2018789388. DOI: 10.1200/JCO.2018.78.9388.

Fusion status in node-positive (n1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: the experience of the European paediatric soft tissue Sarcoma Study Group (EpSSG)

Gallego Melcón S, Zanetti I, Orbach D, Ranchère D, Shipley J, Zin A, Bergeron C, De Salvo GL, Chisholm J, Ferrari A, Jenney M, Mandeville HC, Rogers T, Merks JH, Mudry P, Glosli H, Milano GM, Ferman S, Bisogno G, on behalf of the EpSSG (European Paediatric Soft Tissue Sarcoma Study Group), Fusion status in node-positive (n1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: the experience of the European paediatric soft tissue Sarcoma Study Group (EpSSG). Cancer. 2018. DOI: 10.1002/cncr.31553.

The Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicenter, open-label, randomized controlled, phase 3 trial

Bisogno G, Jenney M, Bergeron C, Gallego Melcón S, Ferrari A, Oberlin O, Carli M, Stevens M, Kelsey A, De Paoli A, Gaze MN, Martelli H, Devalck C, Merks JH, Ben-Arush M, Glosli H, Chisholm J, Orbach D, Minard-Colin V, De Salvo GL, for the EpSSG. The Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicenter, open-label, randomized controlled, phase 3 trial. Lancet Oncol. 2018. pii: S1470-2045(18)30337-1. DOI: 10.1016/S1470-2045(18)30337-1

Genomic complexity in pediatric synovial sarcomas (SYNOBIO study): the European Pediatric Soft tissue Sarcoma Group (EpSSG) experience

Orbach D, Mosseri V, Pissaloux D, Pierron G, Brennan B, Ferrari A, Chibon F, Bisogno G, De Salvo GL, Chakiba C, MD, Corradini N, Minard-Colin V, Kelsey A,Ranchère-Vince D. Genomic complexity in pediatric synovial sarcomas (SYNOBIO study): the European Pediatric Soft tissue Sarcoma Group (EpSSG) experience. Cancer Medicine. 2017. DOI: 10.1002/cam4.1415

Alveolar Soft Part Sarcoma in children and adolescents: the European Paediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005)

Brennan B, Zanetti I, Orbach D, Gallego S, Francotte N, Van Noesel M, Kelsey A, Casanova M, De Salvo GL, Bisogno G, Ferrari A. Alveolar Soft Part Sarcoma in children and adolescents: the European Paediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005). Pediatr Blood Cancer. 2017 e26942. DOI:101002/pbc.26942

Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study)

Chisholm J, Merks JHM, Casanova M, Bisogno G, Orbach D, Gentet JC, Thomassin-Defachelles A, Chastagner P, Lowis S, Ronghe M, McHugh K, van Rijn RR, Hilton M, Bachir J, Furst-Recktenwald S, Geoerger B, Oberlin O. Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study). Eur J of Cancer. 2017 Sept 83:177-184. DOI: 10.1016/j.ejca.2017.06.015

The EpSSG NRSTS 2005 treatment protocol for desmoid-type fibromatosis in children: an international prospective case series

Orbach D, Brennan B, Bisogno G, Van Noesel M, Minard-Colin V, Daragjati J, Casanova M, Corradini N, Zanetti I, De Salvo GL, Defachelles AS, Kelsey A, Ben Arush M, Francotte N, Ferrari A. The EpSSG NRSTS 2005 treatment protocol for desmoid-type fibromatosis in children: an international prospective case series. The Lancet child-adol. 2017 Sept DOI:org/10.1016/S2352-4642(17)30045-7

Surgery alone is sufficient therapy for children and adolescents with low-risk synovial sarcoma: A joint analysis from the European paediatric soft tissue sarcoma Study Group and the Children's Oncology Group

Ferrari A, Chi YY, De Salvo GL, Orbach D, Brennan B, Randall RL, McCarville MB, Black JO, Alaggio R, Hawkins DS, Bisogno G, Spunt SL. Surgery alone is sufficient therapy for children and adolescents with low-risk synovial sarcoma: A joint analysis from the European paediatric soft tissue sarcoma Study Group and the Children's Oncology Group. Eur J Cancer. 2017 Apr 6;78:1-6. DOI: 10.1016/j.ejca.2017.03.003

Access to clinical trials for adolescents with Soft tissue sarcomas: enrollment in European pediatric Soft tissue sarcoma Study Group (EpSSG) protocols

Ferrari A, Trama, De Paoli, Bergeron, Merks, Jenney, Orbach, Chisholm, Gallego, Glosli, De Salvo, Botta, Gatta, Bisogno. Access to clinical trials for adolescents with Soft tissue sarcomas: enrollment in European pediatric Soft tissue sarcoma Study Group (EpSSG) protocols. Pediatr Blood Cancer. 2017 Jun;64(6). DOI: 10.1002/pbc.26348

Outcome of extracranial malignant rhabdoid tumours in children registered in the European Paediatric Soft Tissue Sarcoma Study Group Non-Rhabdomyosarcoma Soft Tissue Sarcoma 2005 Study-EpSSG NRSTS 2005

Brennan B, De Salvo GL, Orbach D, De Paoli A, Kelsey A, Mudry P, Francotte N, Van Noesel M, Bisogno G, Casanova M, Ferrari A. Outcome of extracranial malignant rhabdoid tumours in children registered in the European Paediatric Soft Tissue Sarcoma Study Group Non-Rhabdomyosarcoma Soft Tissue Sarcoma 2005 Study-EpSSG NRSTS 2005. Eur J Cancer. 2016 Jun;60:69-82. DOI: 10.1016/j.ejca.2016.02.027

Conservative strategy in infantile fibrosarcoma is possible: The European paediatric Soft tissue sarcoma Study Group experience

Orbach D, Brennan B, De Paoli A, Gallego S, Mudry P, Francotte N, van Noesel M, Kelsey A, Alaggio R, Ranchère D, De Salvo GL, Casanova M, Bergeron C, Merks, JH, Jenney M, Stevens MC, Bisogno G, Ferrari A. Conservative strategy in infantile fibrosarcoma is possible: The European paediatric Soft tissue sarcoma Study Group experience. Eur J Cancer. 2016 Apr;57:1-9. DOI: 10.1016/j.ejca.2015.12.028

Synovial sarcoma in children and adolescents: the European Pediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005)

Ferrari A, De Salvo GL, Brennan B, van Noesel MM, De Paoli A, Casanova M, Francotte N, Kelsey A, Alaggio R, Oberlin O, Carli M, Ben-Arush M, Bergeron C, Merks JH, Jenney M, Stevens MC, Bisogno G, Orbach D. Synovial sarcoma in children and adolescents: the European Pediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005). Ann Oncol. 2015 Mar;26(3):567-72. DOI: 10.1093/annonc/mdu562

Surgical compliance with guidelines for paratesticular rhabdomyosarcoma (RMS). Data from the European Study on non-metastatic RMS

Cecchetto G, De Corti F, Rogers T, Martelli H. Surgical compliance with guidelines for paratesticular rhabdomyosarcoma (RMS). Data from the European Study on non-metastatic RMS. J Pediatr Surg. 2012 Nov;47(11):2161-2. DOI: 10.1016/j.jpedsurg.2012.08.004